dimethylmorpholine-3-one | 124657-03-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: dimethylmorpholine-3-one
• 英文别名: dimethylmorpholin-3-one；2,4-Dimethylmorpholin-3-one
• CAS: 124657-03-0
• 化学式: C₆H₁₁NO₂
• 分子量: 129.159
• InChiKey: ACYNBKQSGGOWJE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  dimethylmorpholine-3-one 在 lithium aluminium tetrahydride 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 乙醚 、 正己烷 为溶剂， 反应 12.5h， 生成 2,4-dimethyl-2-(1-hydroxy-1,1-diphenylmethyl)-morpholine
  参考文献：
  名称：

  Dobrev, Alexander; Nechev, Lubomir; Ivanov, Christo, Journal of Chemical Research, Miniprint, 1999, # 3, p. 1001 - 1047

  摘要：

  DOI：

文献信息

• [EN] HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROARYLE SERVANT D'INHIBITEURS D'IRAK, ET LEURS UTILISATIONS
  申请人：MERCK PATENT GMBH

  公开号：WO2017049069A1

  公开（公告）日：2017-03-23

  The present invention relates to compounds of Formula (I) and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.

  本发明涉及式(I)的化合物及其药用可接受的组合物，作为IRAK抑制剂。
• [EN] 1-((S)-1-(3-CHLORO-5-FLUORO-2-((4-(1H-PYRAZOL-1-YL)-2-METHYLQUINOLIN-8-YLOXY)METHYL)PHENYL)ETHYL)-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ (BK) B2 RECEPTOR ANTAGONIST FOR TREATING SKIN DISEASES<br/>[FR] DÉRIVÉS DE 1-((S)-1-(3-CHLORO-5-FLUORO-2-((4-(1H-PYRAZOL-1-YL)-2-MÉTHYLQUINOLIN-8-YLOXY)MÉTHYL)PHÉNYL)ÉTHYL)-IMIDAZOLIDINE-2,4-DIONE ET COMPOSÉS APPARENTÉS SERVANT D'ANTAGONISTE DU RÉCEPTEUR B2 DE LA BRADYKININE (BK) POUR LE TRAITEMENT DE MALADIES DE LA PEAU
  申请人：PHARVARIS GMBH

  公开号：WO2020234479A1

  公开（公告）日：2020-11-26

  The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to said compound(s) for use as in a method of treating a skin disorder; eye disease; ear disease; mouth, throat and respiratory disease; gastrointestinal disease; liver, gallbladder and pancreatic disease; urinary tract and kidney disease; disease of male genitale organs and female genitale organs; disease of the hormone system; metabolic disease; cardiovascular disease; blood disease; lymphatic disease; disorder of the central nervous system; brain disorder; musculoskeletal system disease; allergy disorder; pain; infectious disease; inflammatory disorder; injury; immunology disorder; cancer; hereditary disease; or edema. (I)

  该发明涉及一种符合一般式(I)的化合物，该化合物作为一种激肽酶B2（BK）受体拮抗剂；一种含有该发明化合物中的一个或多个化合物的药物组合物；一种含有至少一种该发明化合物和至少一种其他活性药物成分的联合制剂；以及用于治疗皮肤疾病、眼疾、耳疾、口腔、喉咙和呼吸道疾病、胃肠道疾病、肝脏、胆囊和胰腺疾病、泌尿道和肾脏疾病、男性生殖器官和女性生殖器官疾病、激素系统疾病、代谢性疾病、心血管疾病、血液疾病、淋巴疾病、中枢神经系统紊乱、脑部疾病、肌肉骨骼系统疾病、过敏疾病、疼痛、传染病、炎症性疾病、损伤、免疫学紊乱、癌症、遗传性疾病或水肿的方法中使用的该化合物。 (I)
• LACTAM-SUBSTITUTED DICARBOXYLIC ACIDS AND USE THEREOF
  申请人：Hahn Michael

  公开号：US20100197680A1

  公开（公告）日：2010-08-05

  The present application relates to novel lactam-substituted dicarboxylic acid derivatives, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prevention of cardiovascular disorders.

  本申请涉及新型内酰胺取代的二羧酸衍生物，其制备方法，其用于治疗和/或预防疾病的用途，以及其用于生产治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防心血管疾病。
• MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS
  申请人：Nishida Hidemitsu

  公开号：US20110059958A1

  公开（公告）日：2011-03-10

  The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt or a solvate thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.

  本发明提供了如下式（I）所描述的化合物，或其药学上可接受的盐或溶剂。本发明还提供了包含一种或多种所述化合物的制药组合物，并使用该化合物治疗或预防血栓、栓塞、高凝状态或纤维化变化的方法。
• Organic solvent based ink Composition
  申请人：TOYO INK MFG. CO., LTD.

  公开号：EP1790700A1

  公开（公告）日：2007-05-30

  An ink composition containing an organic solvent and a pigment, which has a little amount of smell, excellent safety and health properties, excellent resin solubility, excellent printing stability and excellent drying properties, causes no corrosion to a printer, and is excellent in adhesion to non-absorbable printing media and good printability, wherein the ink composition comprises as the organic solvent at least one compound selected from compounds represented by the formulae (1) to (3), wherein each of R1, R2, R3, R4, R7 and R8 independently represents an alkylene group having 1 to 4 carbon atoms or an alkenylene group having 2 to 4 carbon atoms and each of R5, R6 and R9 independently represents a hydrogen atom or an alkyl group having 1 to 5 carbon atoms.

  一种含有有机溶剂和颜料的油墨组合物，该组合物气味小、安全卫生性能好、树脂溶解性好、印刷稳定性好、干燥性能好、对印刷机无腐蚀、对不可吸收的印刷介质附着力好、印刷适性好，其中该油墨组合物包括至少一种从式（1）至（3）所代表的化合物中选出的化合物作为有机溶剂、 其中 R1、R2、R3、R4、R7 和 R8 各自独立地代表具有 1 至 4 个碳原子的亚烷基或具有 2 至 4 个碳原子的烯基，R5、R6 和 R9 各自独立地代表氢原子或具有 1 至 5 个碳原子的烷基。